- Home
- EDSA vs MTVA Comparison
EDSA vs MTVA Comparison
Compare EDSA & MTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDSA
- MTVA
- Stock Information
- Founded
- EDSA 2015
- MTVA 2014
- Country
- EDSA Canada
- MTVA United States
- Employees
- EDSA N/A
- MTVA N/A
- Industry
- EDSA Biotechnology: Pharmaceutical Preparations
- MTVA
- Sector
- EDSA Health Care
- MTVA
- Exchange
- EDSA Nasdaq
- MTVA NYSE
- Market Cap
- EDSA 6.2M
- MTVA 7.1M
- IPO Year
- EDSA N/A
- MTVA N/A
- Fundamental
- Price
- EDSA $2.03
- MTVA $0.68
- Analyst Decision
- EDSA Strong Buy
- MTVA Strong Buy
- Analyst Count
- EDSA 1
- MTVA 1
- Target Price
- EDSA $21.00
- MTVA $12.00
- AVG Volume (30 Days)
- EDSA 14.5K
- MTVA 222.8K
- Earning Date
- EDSA 05-14-2025
- MTVA 05-14-2025
- Dividend Yield
- EDSA N/A
- MTVA N/A
- EPS Growth
- EDSA N/A
- MTVA N/A
- EPS
- EDSA N/A
- MTVA N/A
- Revenue
- EDSA N/A
- MTVA N/A
- Revenue This Year
- EDSA N/A
- MTVA N/A
- Revenue Next Year
- EDSA N/A
- MTVA N/A
- P/E Ratio
- EDSA N/A
- MTVA N/A
- Revenue Growth
- EDSA N/A
- MTVA N/A
- 52 Week Low
- EDSA $1.55
- MTVA $0.71
- 52 Week High
- EDSA $5.59
- MTVA $5.30
- Technical
- Relative Strength Index (RSI)
- EDSA 36.85
- MTVA N/A
- Support Level
- EDSA $1.99
- MTVA N/A
- Resistance Level
- EDSA $2.14
- MTVA N/A
- Average True Range (ATR)
- EDSA 0.11
- MTVA 0.00
- MACD
- EDSA -0.03
- MTVA 0.00
- Stochastic Oscillator
- EDSA 21.28
- MTVA 0.00
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
About MTVA METAVIA INC
MetaVia Inc Formerly NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.